Dan Kirby
Vermogen: 611 295 $ op 30-06-2026
Vermogen: 611 295 $ op 30-06-2026
Dan Kirby currently works at Iovance Biotherapeutics, Inc., as Chief Commercial Officer from 2025.
Mr. Kirby also formerly worked at Bristol Myers Squibb Co., as Vice President & Head-US Cell in 2018, Omeros Corp., as Chief Commercial Officer from 2018 to 2020, and Orca Biosystems, Inc., as Chief Commercial Officer.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 11-05-2026 | 146.946 ( 0,03% ) | 611 295 $ | 30-06-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. | Corporate Officer/Principal | 10-02-2025 |
| Bedrijven | Functie | Einde |
|---|---|---|
| OMEROS CORPORATION | Corporate Officer/Principal | 01-01-2020 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01-09-2018 |
Orca Biosystems, Inc.
Orca Biosystems, Inc. BiotechnologyHealth Technology Develops allogeneic T-cell immunotherapies for the treatment of blood cancers | Corporate Officer/Principal | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Omeros Corp.
Omeros Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes small-molecule & protein therapeutics | Health Technology |
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. BiotechnologyHealth Technology Develops biotechnological products for the treatment of cancer | Health Technology |
Orca Biosystems, Inc.
Orca Biosystems, Inc. BiotechnologyHealth Technology Develops allogeneic T-cell immunotherapies for the treatment of blood cancers | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau